➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Colorcon
Harvard Business School
Mallinckrodt
Johnson and Johnson

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PALONOSETRON HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Palonosetron Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00306735 Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. Completed Helsinn Healthcare SA Phase 2 2006-03-01 The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.
NCT00306735 Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. Completed Eisai Inc. Phase 2 2006-03-01 The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.
NCT00343460 APF530 or Palonosetron Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer Completed Heron Therapeutics Phase 3 2006-04-01 RATIONALE: Antiemetic drugs, such as APF530, palonosetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for cancer. It is not yet known whether APF530 is more effective than palonosetron when given together with dexamethasone in preventing nausea and vomiting caused by chemotherapy. PURPOSE: This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
NCT00343863 Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer Completed National Cancer Institute (NCI) N/A 2006-01-01 RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy. PURPOSE: This clinical trial studies how well giving dexamethasone together with ondansetron hydrochloride or palonosetron hydrochloride works in preventing nausea and vomiting in patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast cancer
NCT00343863 Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer Completed University of Washington N/A 2006-01-01 RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy. PURPOSE: This clinical trial studies how well giving dexamethasone together with ondansetron hydrochloride or palonosetron hydrochloride works in preventing nausea and vomiting in patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast cancer
NCT00359567 Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy Completed Taiho Pharmaceutical Co., Ltd. Phase 3 2006-07-01 To compare palonosetron with granisetron hydrochloride as a control in the efficacy of intravenous single dose in preventing acute and delayed gastro-intestinal disorders, such as nausea and vomiting induced by highly emetogenic chemotherapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Palonosetron Hydrochloride

Condition Name

Condition Name for Palonosetron Hydrochloride
Intervention Trials
Chemotherapy-induced Nausea and Vomiting 26
Postoperative Nausea and Vomiting 16
Nausea 10
Vomiting 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Palonosetron Hydrochloride
Intervention Trials
Vomiting 77
Nausea 65
Postoperative Nausea and Vomiting 21
Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Palonosetron Hydrochloride

Trials by Country

Trials by Country for Palonosetron Hydrochloride
Location Trials
United States 221
China 23
Italy 21
Korea, Republic of 16
Russian Federation 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Palonosetron Hydrochloride
Location Trials
Texas 15
Ohio 13
Florida 12
California 11
New York 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Palonosetron Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Palonosetron Hydrochloride
Clinical Trial Phase Trials
Phase 4 18
Phase 3 27
Phase 2/Phase 3 3
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Palonosetron Hydrochloride
Clinical Trial Phase Trials
Completed 52
Recruiting 25
Not yet recruiting 13
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Palonosetron Hydrochloride

Sponsor Name

Sponsor Name for Palonosetron Hydrochloride
Sponsor Trials
Helsinn Healthcare SA 14
Eisai Inc. 11
National Cancer Institute (NCI) 9
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Palonosetron Hydrochloride
Sponsor Trials
Other 118
Industry 50
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Baxter
McKesson
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.